bioAffinity Technologies, Inc. (BIAF)

WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm

bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026

bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL

bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference

BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant

bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

BioAffinity Technologies Stock Skyrockets Wednesday: What's Happening?

bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors

bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung

WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules